Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212649213> ?p ?o ?g. }
- W3212649213 endingPage "1341.e4" @default.
- W3212649213 startingPage "1327" @default.
- W3212649213 abstract "BackgroundAlthough vaccines effectively prevent coronavirus disease 2019 (COVID-19) in healthy individuals, they appear to be less immunogenic in individuals with chronic inflammatory disease (CID) or receiving chronic immunosuppression therapy.MethodsHere we assessed a cohort of 77 individuals with CID treated as monotherapy with chronic immunosuppressive drugs for antibody responses in serum against historical and variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses after immunization with the BNT162b2 mRNA vaccine.FindingsLongitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector function capacity in individuals treated with tumor necrosis factor alpha (TNF-α) inhibitors (TNFi), and this pattern appeared to be worse against the B.1.617.2 delta virus. Within 5 months of vaccination, serum neutralizing titers of all TNFi-treated individuals tested fell below the presumed threshold correlate for antibody-mediated protection. However, TNFi-treated individuals receiving a third mRNA vaccine dose boosted their serum neutralizing antibody titers by more than 16-fold.ConclusionsVaccine boosting or administration of long-acting prophylaxis (e.g., monoclonal antibodies) will likely be required to prevent SARS-CoV-2 infection in this susceptible population.FundingThis study was supported by grants and contracts from the NIH (R01 AI157155, R01AI151178, and HHSN75N93019C00074; NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contracts HHSN272201400008C and 75N93021C00014; and Collaborative Influenza Vaccine Innovation Centers [CIVIC] contract 75N93019C00051)." @default.
- W3212649213 created "2021-11-22" @default.
- W3212649213 creator A5003557652 @default.
- W3212649213 creator A5009302642 @default.
- W3212649213 creator A5009632243 @default.
- W3212649213 creator A5013365298 @default.
- W3212649213 creator A5015092469 @default.
- W3212649213 creator A5019528385 @default.
- W3212649213 creator A5025961798 @default.
- W3212649213 creator A5029821714 @default.
- W3212649213 creator A5032281507 @default.
- W3212649213 creator A5036038306 @default.
- W3212649213 creator A5043016585 @default.
- W3212649213 creator A5049817365 @default.
- W3212649213 creator A5054908190 @default.
- W3212649213 creator A5056698554 @default.
- W3212649213 creator A5059371880 @default.
- W3212649213 creator A5059907217 @default.
- W3212649213 creator A5062246223 @default.
- W3212649213 creator A5063694206 @default.
- W3212649213 creator A5066700121 @default.
- W3212649213 creator A5070153307 @default.
- W3212649213 creator A5071125492 @default.
- W3212649213 creator A5083645637 @default.
- W3212649213 creator A5087485877 @default.
- W3212649213 date "2021-12-01" @default.
- W3212649213 modified "2023-09-26" @default.
- W3212649213 title "Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors" @default.
- W3212649213 cites W1513110336 @default.
- W3212649213 cites W2028910347 @default.
- W3212649213 cites W2052160307 @default.
- W3212649213 cites W2075163956 @default.
- W3212649213 cites W2081732770 @default.
- W3212649213 cites W2101580628 @default.
- W3212649213 cites W2131198668 @default.
- W3212649213 cites W2132919735 @default.
- W3212649213 cites W2585172252 @default.
- W3212649213 cites W2791182624 @default.
- W3212649213 cites W2794305622 @default.
- W3212649213 cites W2911385050 @default.
- W3212649213 cites W2946773123 @default.
- W3212649213 cites W2958051078 @default.
- W3212649213 cites W2963587856 @default.
- W3212649213 cites W3008394341 @default.
- W3212649213 cites W3016269138 @default.
- W3212649213 cites W3024602798 @default.
- W3212649213 cites W3025559601 @default.
- W3212649213 cites W3025631553 @default.
- W3212649213 cites W3025744748 @default.
- W3212649213 cites W3030146162 @default.
- W3212649213 cites W3032255042 @default.
- W3212649213 cites W3040899749 @default.
- W3212649213 cites W3081204841 @default.
- W3212649213 cites W3093768302 @default.
- W3212649213 cites W3095217725 @default.
- W3212649213 cites W3099530525 @default.
- W3212649213 cites W3102798166 @default.
- W3212649213 cites W3121995178 @default.
- W3212649213 cites W3125889898 @default.
- W3212649213 cites W3132982761 @default.
- W3212649213 cites W3133327867 @default.
- W3212649213 cites W3133782701 @default.
- W3212649213 cites W3133794453 @default.
- W3212649213 cites W3133980772 @default.
- W3212649213 cites W3135353939 @default.
- W3212649213 cites W3135940977 @default.
- W3212649213 cites W3139036184 @default.
- W3212649213 cites W3139533040 @default.
- W3212649213 cites W3153508314 @default.
- W3212649213 cites W3156291144 @default.
- W3212649213 cites W3157162195 @default.
- W3212649213 cites W3157709232 @default.
- W3212649213 cites W3160252417 @default.
- W3212649213 cites W3163785571 @default.
- W3212649213 cites W3170724610 @default.
- W3212649213 cites W3172812363 @default.
- W3212649213 cites W3172858351 @default.
- W3212649213 cites W3174747632 @default.
- W3212649213 cites W3175562186 @default.
- W3212649213 cites W3176897911 @default.
- W3212649213 cites W3177181935 @default.
- W3212649213 cites W3177362856 @default.
- W3212649213 cites W3177903130 @default.
- W3212649213 cites W3179639010 @default.
- W3212649213 cites W3182094313 @default.
- W3212649213 cites W3184115715 @default.
- W3212649213 cites W3184172540 @default.
- W3212649213 cites W3184226105 @default.
- W3212649213 cites W3184341293 @default.
- W3212649213 cites W3189985782 @default.
- W3212649213 cites W3190398149 @default.
- W3212649213 cites W3193143175 @default.
- W3212649213 cites W3193422644 @default.
- W3212649213 cites W3195351407 @default.
- W3212649213 cites W3195868522 @default.
- W3212649213 cites W3197081215 @default.
- W3212649213 cites W3197124451 @default.
- W3212649213 cites W3197504359 @default.